These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34395203)

  • 1. What's New in Critical Illness and Injury Science? Mortality effects of tocilizumab for patients admitted with COVID-19 pneumonia.
    Miller AC; D'Silva YA; Gruber EA
    Int J Crit Illn Inj Sci; 2021; 11(2):49-50. PubMed ID: 34395203
    [No Abstract]   [Full Text] [Related]  

  • 2. What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19.
    Miller AC; D'Silva YA
    Int J Crit Illn Inj Sci; 2021; 11(3):109-111. PubMed ID: 34760655
    [No Abstract]   [Full Text] [Related]  

  • 3. What's New in Critical Illness and Injury Science? Delirium, COVID-19, and critical illness.
    Miller AC
    Int J Crit Illn Inj Sci; 2022; 12(2):59-60. PubMed ID: 35845126
    [No Abstract]   [Full Text] [Related]  

  • 4. What's new in critical illness and injury science? Intravenous immunoglobulin for COVID-19 with severe or critical illness.
    Miller AC; Venkatachalam S
    Int J Crit Illn Inj Sci; 2020; 10(4):159-162. PubMed ID: 33850822
    [No Abstract]   [Full Text] [Related]  

  • 5. What's new in critical illness and injury science? Pneumonia prevention in the ICU remains a challenge.
    Ferreira J; Bajwa AA
    Int J Crit Illn Inj Sci; 2016; 6(1):1-2. PubMed ID: 27051614
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.
    Sarhan RM; Madney YM; Abou Warda AE; Boshra MS
    Int J Clin Pract; 2021 Jun; 75(6):e14079. PubMed ID: 33550688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
    Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
    Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients.
    Fisher MJ; Marcos Raymundo LA; Monteforte M; Taub EM; Go R
    Int J Infect Dis; 2021 Feb; 103():536-539. PubMed ID: 33333252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What's New in Critical Illness and Injury Science?:
    Sanjan A; Krishnan VS; Balakrishnan JM; Stawicki SP; Sirur FM; Lateef F; Goncalves RV; Galwankar S
    Int J Crit Illn Inj Sci; 2020; 10(3):105-108. PubMed ID: 33409124
    [No Abstract]   [Full Text] [Related]  

  • 10. What's New in Critical Illness and Injury Science? Mental health and COVID-19: Self-inflicted and interpersonal violence amid a pandemic.
    Papadimos TJ
    Int J Crit Illn Inj Sci; 2020; 10(2):45-48. PubMed ID: 32904505
    [No Abstract]   [Full Text] [Related]  

  • 11. What's new in critical illness and injury science? Driving characteristics and rates of road traffic accidents and associated serious injuries and fatalities during the COVID-19 pandemic.
    Miller AC
    Int J Crit Illn Inj Sci; 2021; 11(4):189-190. PubMed ID: 35070906
    [No Abstract]   [Full Text] [Related]  

  • 12. What's new in critical illness and injury science? The effect of concomitant natural and manmade disasters on chronic disease exacerbations: COVID-19, armed conflicts, refugee crises and research needs.
    Miller AC
    Int J Crit Illn Inj Sci; 2022; 12(1):1-3. PubMed ID: 35433393
    [No Abstract]   [Full Text] [Related]  

  • 13. Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab.
    Sandhu G; Piraino ST; Piticaru J
    Am J Ther; 2022 May-Jun 01; 29(3):e275-e278. PubMed ID: 35249968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new in critical illness and injury science? Convalescent plasma for coronavirus disease-2019 patients with severe or critical illness.
    Miller AC; Ghadermarzi S; Venkatachalam S
    Int J Crit Illn Inj Sci; 2021; 11(1):1-3. PubMed ID: 34159128
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of tocilizumab on intensive care patients with Covid-19 pneumonia, a retrospective cohort study.
    Küçük MP; Küçük AO; Pehlivanlar A; Mürtezaoğlu SA; Çoban K; Kılıç G; Ayçiçek O; Öztuna F; Bülbül Y; Özlü T
    Turk J Med Sci; 2022 Feb; 52(1):39-49. PubMed ID: 36161598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab: A retrospective multi-center cohort study of critically ill patients with COVID-19.
    Villatoro Santos CR; Bhargava A; Coyle M; Szpunar S; Saravolatz LD
    Int J Clin Pharmacol Ther; 2021 Nov; 59(11):705-712. PubMed ID: 34448693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study.
    Rojas-Marte G; Khalid M; Mukhtar O; Hashmi AT; Waheed MA; Ehrlich S; Aslam A; Siddiqui S; Agarwal C; Malyshev Y; Henriquez-Felipe C; Sharma D; Sharma S; Chukwuka N; Rodriguez DC; Alliu S; Le J; Shani J
    QJM; 2020 Aug; 113(8):546-550. PubMed ID: 32569363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
    Cardona-Pascual I; Berlana D; Martinez-Valle F; Campany-Herrero D; Montoro-Ronsano JB
    Med Clin (Engl Ed); 2022 Apr; 158(7):301-307. PubMed ID: 35531306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab and liver injury in patients with COVID-19.
    Serviddio G; Villani R; Stallone G; Scioscia G; Foschino-Barbaro MP; Lacedonia D
    Therap Adv Gastroenterol; 2020; 13():1756284820959183. PubMed ID: 33101458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.